Pharmaco 
 GenomeX2


Make Drug Therapy Safe & Efficient
through Implementation of Algorithms
of Personalized Pharmacotherapy

GET PGX2 REPORT



PGX2 – is a bioinformatic cloud service for data analysis and interpretation of pharmacogenetic test performed on the basis of SNP's (real-time PCR) or NGS, with additional estimated risks of polypragmasia.

OUR MISSION

Make safe and efficient drug therapy available in every doctor's routine practice.



Empirical selection of pharmacotherapy is associated with a high risk of adverse drug reactions (ADRs) and pharmacoresistance. Drugs fail to treat and cause ADRs due to individual variability in drug response and toxic reactions and based on a genetic polymorphisms profile, that predetermines the metabolic transformation, pharmacodynamics and medicine conjugation. Numerous studies of the influence of all the genes related to the individual response of a particular patient to a particular drug have shown that such problems are faced by every 5 people in the European population (a mutation of the CYP2D6 gene).

image hand




do not show the desired therapeutic effect and cause ADRs. Safe and efficient treatment demands preliminary genetic testing to achieve personalization of drug therapy and avoid the consequences of polypragmasia and pharmacoresistance.




PRODUCT


Software that enables to analyse and interpret you DNA test results (on the basis of 154 polymorphisims) and generates a report that includes 52 drug groups with 655 drugs (more than 5000 generics) of 8 nosologies (psychiatry, neurology, cardiology, alergology, gastroenterology, endocrinology, dermatology and infectious diseases), which is by far the largest database of pharmacogenetic biomarkers in the world.





HOW IT WORKS



TECHOLOGY

img
Q&A





EVIDENCE BASED DATA

The strongest team of multidisciplinary pharmacogenetics, who are the most cited and productive researchers in various areas of pharmacotherapy (narcology, psychiatry, cardiology, neurology, gynecology, etc) in the Russian Federation and the CIS countries, contributes to the creation of a daily updated scientific basis of PGX2.

The PGX2 team has over 100 scientific publications in just 2 years of collaboration. The technology allows to integrate machine deep learning with advanced knowledge of the world pharmacogenetics of Level of evidence 1 to the daily practice of physicians.





OUR PUBLICATIONS




ALL ARTICLES







MEDIA


rbk logo image
kommersant logo image

vc logo image




NEWS


21.10.2020

PGX2 team as a participant at Open innovation 2020.



20.10.2020

PGX2 won a grant for further development and commercialization of its innovations.



24.09.2020

PGX2 solution is marked on the digital health map 2020.



21.09.2020

PGX2 was included in the contour of innovative solutions of the Moscow Innovation Agency.



ALL NEWS







TEAM


zastrozhin's photo

Mikhael Zastrozhin

FOUNDER, СЕО

PhD, more than 120 articles.


Valentin Scryabin

SCIENCE DIRECTOR

psychiatrist, clinical pharmacologist, more than 50 articles.

skryabin's photo

panchenko's photo

Alla Panchenko

BUSINESS DEVELOPMENT

PR and GR management, project management, 8 years of practice in the healthcare market of the Russian Federation, CIS and Asia.

JOBS




© 2020 All Rights Reserved